Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

Summary

This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

Timeline

Start

2018-01-30

Primary completion

2021-10-26

Completion

2021-10-26

Drugs

Indications